A 2-part Phase 1/2 Open-label Trial on ODM-212
A 2-part Phase 1/2 Open-label Trial on ODM-212
Recruiting · NCT07563738 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 2-part Phase 1/2 Open-label Trial on ODM-212 | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, epithelial neoplasm, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-04 | NCT07563738 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Orion Corporation, Orion Pharma | 5 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NEXT Oncology | Irving | United States | 11 |
| NEXT Oncology Virginia | Fairfax | United States | 40 |